Cargando…
Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
BACKGROUND: Given the increasing use of immune checkpoint inhibitors (ICIs), a concomitant rise in adverse events is inevitable. In a recent Phase III trial of ICIs versus placebo, we found the staggering difference of incidence of fatal adverse events (FAEs). Hence, we should determine the risk of...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385768/ https://www.ncbi.nlm.nih.gov/pubmed/30858709 http://dx.doi.org/10.2147/TCRM.S191022 |